Literature DB >> 11544417

Copolymer 1 inhibits manifestations of graft rejection.

R Aharoni1, D Teitelbaum, R Arnon, M Sela.   

Abstract

BACKGROUND: Copolymer 1 (Cop 1) was previously shown to prevent graft-versus-host disease and interfere in various manifestations of immune rejection. In this study, we tested whether Cop 1 can also hinder the reactivity of host against graft and inhibit graft rejection.
METHODS: Cop 1 was tested in two transplantation systems: skin and thyroid grafting assays. The effect of Cop 1 on T cell reactivity was investigated by proliferation and cytokine secretion of spleen and lymph node cells from transplanted mice, as well as the T cell lines generated therefrom.
RESULTS: Cop 1 treatment prolonged skin graft survival and inhibited the functional deterioration of thyroid grafts, in various strain combinations, across minor and major histocompatibility barriers, similarly to the potent immunosuppressive drug FK506. Cop 1 inhibited the proliferation of graft-specific T cell lines, as well as their interleukin (IL)-2 and interferon-gamma (IFN-gamma) secretion, when incubated in vitro with the stimulating allogeneic cells. Spleen and lymph node cells from Cop 1-treated mice, as well as the T cell lines generated from them, demonstrated a pronounced inhibition of proliferation and secretion of T helper (Th)1 cytokines in response to graft cells. In addition, cells from Cop 1-treated mice secreted high amounts of Th2 cytokines in response to Cop 1 and small but significant amounts of Th2 cytokines, mainly IL-10, in response to allograft cells.
CONCLUSIONS: Cop 1 treatment inhibited the Th1 response to graft and induced a Th2 cytokines secretion in response to both Cop 1 and graft cells, leading to improved survival and function of the transplanted grafts.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11544417     DOI: 10.1097/00007890-200108270-00007

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  3 in total

1.  Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications.

Authors:  Ruth Arnon; Rina Aharoni
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-15       Impact factor: 11.205

Review 2.  Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system?

Authors:  Babak Jalilian; Halldór Bjarki Einarsson; Thomas Vorup-Jensen
Journal:  Int J Mol Sci       Date:  2012-11-09       Impact factor: 5.923

3.  Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study.

Authors:  Peter Lackner; Andrea Part; Christoph Burger; Anelia Dietmann; Gregor Broessner; Raimund Helbok; Markus Reindl; Erich Schmutzhard; Ronny Beer
Journal:  Malar J       Date:  2009-02-27       Impact factor: 2.979

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.